Electra Therapeutics has completed a $350 million IPO on Nasdaq, positioning the inflammation-focused company to fund commercialization and late-stage execution. The listing adds to a busy 2026 pipeline of large, oversubscribed biotech stock debuts, reflecting sustained investor appetite for near-commercial platforms. Separate coverage notes that Electra’s IPO followed a larger pattern of biotech companies raising $300 million-plus in 2026, with IPO proceeds increasingly being used to scale operations rather than only sustain early development. The new funding is expected to accelerate Electra’s transition into a commercial biotech model. The IPO timing also underscores how investors are funding inflammation franchises with clearer pathways to market rather than purely platform risk, particularly as public markets look for validation signals beyond preclinical differentiation.